The use of escitalopram beyond major depression: Pharmacological aspects, efficacy and tolerability in anxiety disorders

被引:16
|
作者
Bareggi, Silvio R.
Mundo, Emanuela
Dell'Osso, Bernardo
Altamura, A. Carlo
机构
[1] Univ Milan, Dept Pharmacol, I-20129 Milan, Italy
[2] Univ Milan, Dept Psychiat, Dept Clin Sci Luigi Sacco, Milan, Italy
关键词
escitalopram; generalised anxiety disorder; obsessive-compulsive disorder; panic disorder; pharmacodynamics; pharmacokinetics; social phobia; SSRIs;
D O I
10.1517/17425225.3.5.741
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughout the world for the treatment of depression and anxiety disorders. It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H 1 and muscarinic receptors. Escitalopram has favourable pharmacokinetics: it is rapidly absorbed, has a bioavailability of 80% and is not affected by food intake. It has little potential for drug interactions: it has low protein binding and, as it is metabolised by three CYP isozymes, any impairment in the activity of one is unlikely to have a significant effect on metabolic clearance. Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment. The multiple-dose pharmacokinetics of oral escitalopram are proportional at a range of doses including its therapeutic doses. Escitalopram is approved for the treatment of a number of anxiety disorders. It seems to be well tolerated and induces few or no discontinuation symptoms, and may be considered a first-line agent for the pharmacotherapy of obsessive-compulsive disorder, generalised anxiety disorder, panic disorder and social phobia. Further studies are needed to define its activity in impulse control disorders.
引用
收藏
页码:741 / 753
页数:13
相关论文
共 50 条
  • [41] Personality disorders in adolescents with major depression, substance use disorders, and coexisting major depression and substance use disorders
    Grilo, CM
    Walker, ML
    Becker, DF
    Edell, WS
    McGlashan, TH
    JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1997, 65 (02) : 328 - 332
  • [42] Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder
    Stein, Dan J.
    Lopez, Ana Garcia
    ADVANCES IN THERAPY, 2011, 28 (11) : 1021 - 1037
  • [43] Efficacy of mirtazapine combined with escitalopram in the treatment of sleep disorders in patients with depression
    Xie, Sisi
    Liu, Yong
    MINERVA SURGERY, 2022,
  • [44] Efficacy of mirtazapine combined with escitalopram in the treatment of sleep disorders in patients with depression
    Xie, Sisi
    Liu, Yong
    MINERVA SURGERY, 2024, 79 (02): : 241 - 243
  • [45] PHARMACOGENETIC INFLUENCES ON SERTRALINE EFFICACY AND TOLERABILITY IN YOUTH WITH ANXIETY AND DEPRESSION
    Strawn, Jeffrey Robert
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S301 - S302
  • [46] Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
    Fava, M
    Rosenbaum, JF
    Hoog, SL
    Tepner, RG
    Kopp, JB
    Nilsson, ME
    JOURNAL OF AFFECTIVE DISORDERS, 2000, 59 (02) : 119 - 126
  • [47] Dorsomedial Prefrontal rTMS in Major Depression: Safety, Efficacy, and Tolerability
    Downar, Jonathan
    Giacobbe, Peter
    Salomons, Tim
    Kennedy, Sidney
    Flint, Alastair
    BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 28S - 28S
  • [48] Citalopram and suicidality in adult major depression and anxiety disorders
    Pedersen, Anders G.
    NORDIC JOURNAL OF PSYCHIATRY, 2006, 60 (05) : 392 - 399
  • [49] COMORBIDITY OF MAJOR DEPRESSION AND ANXIETY DISORDERS IN TWIN PAIRS
    TORGERSEN, S
    AMERICAN JOURNAL OF PSYCHIATRY, 1990, 147 (09): : 1199 - 1202
  • [50] Prevalence and comorbidity of major depression and anxiety disorders in the postpartum
    Xavier, S.
    Soares, M. J.
    Azevedo, J.
    Marques, C.
    Meneses, S.
    Marques, M.
    Macedo, A.
    Pereira, A. T.
    EUROPEAN PSYCHIATRY, 2019, 56 : S319 - S320